Does the media refer more to ASND or IOVA?

In the previous week, Iovance Biotherapeutics had 20 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 28 mentions for Iovance Biotherapeutics and 8 mentions for Ascendis Pharma A/S. Iovance Biotherapeutics' average media sentiment score of 0.63 beat Ascendis Pharma A/S's score of 0.20 indicating that Iovance Biotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ascendis Pharma A/S 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Iovance Biotherapeutics 8 Very Positive mention(s) 7 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor IOVA or EXEL?

In the previous week, Iovance Biotherapeutics had 25 more articles in the media than Exelixis. MarketBeat recorded 28 mentions for Iovance Biotherapeutics and 3 mentions for Exelixis. Exelixis' average media sentiment score of 0.83 beat Iovance Biotherapeutics' score of 0.63 indicating that Exelixis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Iovance Biotherapeutics 8 Very Positive mention(s) 7 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Exelixis 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor IOVA or SMMT?

In the previous week, Iovance Biotherapeutics had 15 more articles in the media than Summit Therapeutics. MarketBeat recorded 28 mentions for Iovance Biotherapeutics and 13 mentions for Summit Therapeutics. Iovance Biotherapeutics' average media sentiment score of 0.63 beat Summit Therapeutics' score of 0.56 indicating that Iovance Biotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Iovance Biotherapeutics 8 Very Positive mention(s) 7 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Summit Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media favor IOVA or BBIO?

In the previous week, Iovance Biotherapeutics had 20 more articles in the media than BridgeBio Pharma. MarketBeat recorded 28 mentions for Iovance Biotherapeutics and 8 mentions for BridgeBio Pharma. BridgeBio Pharma's average media sentiment score of 0.73 beat Iovance Biotherapeutics' score of 0.63 indicating that BridgeBio Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Iovance Biotherapeutics 8 Very Positive mention(s) 7 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BridgeBio Pharma 1 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to HALO or IOVA?

In the previous week, Iovance Biotherapeutics had 22 more articles in the media than Halozyme Therapeutics. MarketBeat recorded 28 mentions for Iovance Biotherapeutics and 6 mentions for Halozyme Therapeutics. Halozyme Therapeutics' average media sentiment score of 0.73 beat Iovance Biotherapeutics' score of 0.63 indicating that Halozyme Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Halozyme Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Iovance Biotherapeutics 8 Very Positive mention(s) 7 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Iovance Biotherapeutics (IOVA) Competitors

$14.46 +0.02 (+0.10%)

As of 10:22 AM Eastern

Compare

IOVA vs. ASND, EXEL, SMMT, BBIO, and HALO

Should you buy Iovance Biotherapeutics stock or one of its competitors? Iovance Biotherapeutics's main competitors and comparable companies include Ascendis Pharma A/S (ASND), Exelixis (EXEL), Summit Therapeutics (SMMT), BridgeBio Pharma (BBIO), and Halozyme Therapeutics (HALO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Iovance Biotherapeutics compare to Ascendis Pharma A/S?

Ascendis Pharma A/S (NASDAQ:ASND) and Iovance Biotherapeutics (NASDAQ:IOVA) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, media sentiment, valuation, analyst recommendations, risk and institutional ownership.

Ascendis Pharma A/S has a beta of 0.35, meaning that its stock price is 65% less volatile than the broader market. Comparatively, Iovance Biotherapeutics has a beta of 0.83, meaning that its stock price is 17% less volatile than the broader market.

Ascendis Pharma A/S has a net margin of 70.99% compared to Iovance Biotherapeutics' net margin of -89.11%. Ascendis Pharma A/S's return on equity of 32.54% beat Iovance Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	70.99%	32.54%	7.71%
Iovance Biotherapeutics	-89.11%	-40.51%	-31.65%

Ascendis Pharma A/S presently has a consensus target price of $310.75, suggesting a potential upside of 36.62%. Iovance Biotherapeutics has a consensus target price of $11.78, suggesting a potential downside of 18.58%. Given Ascendis Pharma A/S's stronger consensus rating and higher possible upside, equities research analysts clearly believe Ascendis Pharma A/S is more favorable than Iovance Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	3.00
Iovance Biotherapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

In the previous week, Iovance Biotherapeutics had 20 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 28 mentions for Iovance Biotherapeutics and 8 mentions for Ascendis Pharma A/S. Iovance Biotherapeutics' average media sentiment score of 0.63 beat Ascendis Pharma A/S's score of 0.20 indicating that Iovance Biotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascendis Pharma A/S	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral
Iovance Biotherapeutics	8 Very Positive mention(s)	7 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ascendis Pharma A/S has higher revenue and earnings than Iovance Biotherapeutics. Iovance Biotherapeutics is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$814.57M	17.42	-$258M	$12.89	17.65
Iovance Biotherapeutics	$263.50M	24.87	-$390.98M	-$0.73	N/A

77.0% of Iovance Biotherapeutics shares are held by institutional investors. 40.0% of Ascendis Pharma A/S shares are held by insiders. Comparatively, 7.8% of Iovance Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Ascendis Pharma A/S beats Iovance Biotherapeutics on 12 of the 17 factors compared between the two stocks.

How does Iovance Biotherapeutics compare to Exelixis?

Iovance Biotherapeutics (NASDAQ:IOVA) and Exelixis (NASDAQ:EXEL) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, valuation, media sentiment, profitability and risk.

Exelixis has higher revenue and earnings than Iovance Biotherapeutics. Iovance Biotherapeutics is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Iovance Biotherapeutics	$263.50M	24.87	-$390.98M	-$0.73	N/A
Exelixis	$2.44B	6.00	$782.57M	$3.18	18.56

Iovance Biotherapeutics currently has a consensus price target of $11.78, indicating a potential downside of 18.58%. Exelixis has a consensus price target of $50.29, indicating a potential downside of 14.80%. Given Exelixis' higher possible upside, analysts plainly believe Exelixis is more favorable than Iovance Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Iovance Biotherapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Exelixis	1 Sell rating(s)	12 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.35

Exelixis has a net margin of 35.33% compared to Iovance Biotherapeutics' net margin of -89.11%. Exelixis' return on equity of 42.17% beat Iovance Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Iovance Biotherapeutics	-89.11%	-40.51%	-31.65%
Exelixis	35.33%	42.17%	31.76%

In the previous week, Iovance Biotherapeutics had 25 more articles in the media than Exelixis. MarketBeat recorded 28 mentions for Iovance Biotherapeutics and 3 mentions for Exelixis. Exelixis' average media sentiment score of 0.83 beat Iovance Biotherapeutics' score of 0.63 indicating that Exelixis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Iovance Biotherapeutics	8 Very Positive mention(s)	7 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Exelixis	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

77.0% of Iovance Biotherapeutics shares are held by institutional investors. Comparatively, 85.3% of Exelixis shares are held by institutional investors. 7.8% of Iovance Biotherapeutics shares are held by insiders. Comparatively, 2.6% of Exelixis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Iovance Biotherapeutics has a beta of 0.83, suggesting that its stock price is 17% less volatile than the broader market. Comparatively, Exelixis has a beta of 0.42, suggesting that its stock price is 58% less volatile than the broader market.

Summary

Exelixis beats Iovance Biotherapeutics on 11 of the 17 factors compared between the two stocks.

How does Iovance Biotherapeutics compare to Summit Therapeutics?

Iovance Biotherapeutics (NASDAQ:IOVA) and Summit Therapeutics (NASDAQ:SMMT) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, analyst recommendations, valuation, profitability, dividends and risk.

Iovance Biotherapeutics has higher revenue and earnings than Summit Therapeutics. Iovance Biotherapeutics is trading at a lower price-to-earnings ratio than Summit Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Iovance Biotherapeutics	$263.50M	24.87	-$390.98M	-$0.73	N/A
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.12	N/A

Summit Therapeutics has a net margin of 0.00% compared to Iovance Biotherapeutics' net margin of -89.11%. Iovance Biotherapeutics' return on equity of -40.51% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Iovance Biotherapeutics	-89.11%	-40.51%	-31.65%
Summit Therapeutics	N/A	-168.94%	-141.92%

In the previous week, Iovance Biotherapeutics had 15 more articles in the media than Summit Therapeutics. MarketBeat recorded 28 mentions for Iovance Biotherapeutics and 13 mentions for Summit Therapeutics. Iovance Biotherapeutics' average media sentiment score of 0.63 beat Summit Therapeutics' score of 0.56 indicating that Iovance Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Iovance Biotherapeutics	8 Very Positive mention(s)	7 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Summit Therapeutics	5 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

77.0% of Iovance Biotherapeutics shares are held by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are held by institutional investors. 7.8% of Iovance Biotherapeutics shares are held by company insiders. Comparatively, 83.5% of Summit Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Iovance Biotherapeutics has a beta of 0.83, suggesting that its share price is 17% less volatile than the broader market. Comparatively, Summit Therapeutics has a beta of -1.24, suggesting that its share price is 224% less volatile than the broader market.

Iovance Biotherapeutics currently has a consensus target price of $11.78, indicating a potential downside of 18.58%. Summit Therapeutics has a consensus target price of $28.45, indicating a potential upside of 66.86%. Given Summit Therapeutics' higher probable upside, analysts plainly believe Summit Therapeutics is more favorable than Iovance Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Iovance Biotherapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Summit Therapeutics	1 Sell rating(s)	8 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.53

Summary

Iovance Biotherapeutics beats Summit Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Iovance Biotherapeutics compare to BridgeBio Pharma?

Iovance Biotherapeutics (NASDAQ:IOVA) and BridgeBio Pharma (NASDAQ:BBIO) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, dividends, profitability, media sentiment, risk and valuation.

Iovance Biotherapeutics has a beta of 0.83, meaning that its share price is 17% less volatile than the broader market. Comparatively, BridgeBio Pharma has a beta of 0.97, meaning that its share price is 3% less volatile than the broader market.

Iovance Biotherapeutics has a net margin of -89.11% compared to BridgeBio Pharma's net margin of -97.03%. BridgeBio Pharma's return on equity of 0.00% beat Iovance Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Iovance Biotherapeutics	-89.11%	-40.51%	-31.65%
BridgeBio Pharma	-97.03%	N/A	-61.19%

In the previous week, Iovance Biotherapeutics had 20 more articles in the media than BridgeBio Pharma. MarketBeat recorded 28 mentions for Iovance Biotherapeutics and 8 mentions for BridgeBio Pharma. BridgeBio Pharma's average media sentiment score of 0.73 beat Iovance Biotherapeutics' score of 0.63 indicating that BridgeBio Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Iovance Biotherapeutics	8 Very Positive mention(s)	7 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BridgeBio Pharma	1 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Iovance Biotherapeutics has higher earnings, but lower revenue than BridgeBio Pharma. Iovance Biotherapeutics is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Iovance Biotherapeutics	$263.50M	24.87	-$390.98M	-$0.73	N/A
BridgeBio Pharma	$713.07M	18.15	-$724.93M	-$3.57	N/A

77.0% of Iovance Biotherapeutics shares are owned by institutional investors. Comparatively, 99.8% of BridgeBio Pharma shares are owned by institutional investors. 7.8% of Iovance Biotherapeutics shares are owned by insiders. Comparatively, 14.2% of BridgeBio Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Iovance Biotherapeutics presently has a consensus price target of $11.78, indicating a potential downside of 18.58%. BridgeBio Pharma has a consensus price target of $102.61, indicating a potential upside of 54.96%. Given BridgeBio Pharma's stronger consensus rating and higher possible upside, analysts clearly believe BridgeBio Pharma is more favorable than Iovance Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Iovance Biotherapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83

Summary

BridgeBio Pharma beats Iovance Biotherapeutics on 10 of the 16 factors compared between the two stocks.

How does Iovance Biotherapeutics compare to Halozyme Therapeutics?

Halozyme Therapeutics (NASDAQ:HALO) and Iovance Biotherapeutics (NASDAQ:IOVA) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, valuation, risk, institutional ownership, dividends, analyst recommendations and media sentiment.

Halozyme Therapeutics has higher revenue and earnings than Iovance Biotherapeutics. Iovance Biotherapeutics is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Halozyme Therapeutics	$1.40B	9.00	$316.89M	$3.35	33.07
Iovance Biotherapeutics	$263.50M	24.87	-$390.98M	-$0.73	N/A

Halozyme Therapeutics has a net margin of 24.86% compared to Iovance Biotherapeutics' net margin of -89.11%. Halozyme Therapeutics' return on equity of 260.98% beat Iovance Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Halozyme Therapeutics	24.86%	260.98%	23.91%
Iovance Biotherapeutics	-89.11%	-40.51%	-31.65%

In the previous week, Iovance Biotherapeutics had 22 more articles in the media than Halozyme Therapeutics. MarketBeat recorded 28 mentions for Iovance Biotherapeutics and 6 mentions for Halozyme Therapeutics. Halozyme Therapeutics' average media sentiment score of 0.73 beat Iovance Biotherapeutics' score of 0.63 indicating that Halozyme Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Halozyme Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Iovance Biotherapeutics	8 Very Positive mention(s)	7 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Halozyme Therapeutics presently has a consensus target price of $91.20, suggesting a potential downside of 17.68%. Iovance Biotherapeutics has a consensus target price of $11.78, suggesting a potential downside of 18.58%. Given Halozyme Therapeutics' higher possible upside, equities analysts clearly believe Halozyme Therapeutics is more favorable than Iovance Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Halozyme Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62
Iovance Biotherapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

97.8% of Halozyme Therapeutics shares are held by institutional investors. Comparatively, 77.0% of Iovance Biotherapeutics shares are held by institutional investors. 2.5% of Halozyme Therapeutics shares are held by insiders. Comparatively, 7.8% of Iovance Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Halozyme Therapeutics has a beta of 0.88, meaning that its stock price is 12% less volatile than the broader market. Comparatively, Iovance Biotherapeutics has a beta of 0.83, meaning that its stock price is 17% less volatile than the broader market.

Summary

Halozyme Therapeutics beats Iovance Biotherapeutics on 12 of the 16 factors compared between the two stocks.

Get Iovance Biotherapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IOVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IOVA vs. The Competition

Export

Metric	Iovance Biotherapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$6.54B	$3.94B	$7.26B	$13.16B
Dividend Yield	N/A	3.63%	2.52%	14.18%
P/E Ratio	-19.77	13.80	274.16	25.79
Price / Sales	24.87	1,303.77	616.66	75.52
Price / Cash	N/A	121.91	80.06	52.35
Price / Book	8.22	15.31	10.47	6.35
Net Income	-$390.98M	-$22.71M	$3.50B	$360.56M
7 Day Performance	41.95%	-1.86%	-1.44%	-1.48%
1 Month Performance	80.59%	-8.24%	-4.26%	-3.99%
1 Year Performance	566.59%	26.44%	12.56%	3.95%

Iovance Biotherapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IOVA Iovance Biotherapeutics	1.5623 of 5 stars	$14.34 -0.7%	$11.78 -17.9%	+548.0%	$6.52B	$263.50M	N/A	975	Trending News Analyst Forecast Gap Up
ASND Ascendis Pharma A/S	4.8251 of 5 stars	$237.59 +0.4%	$310.75 +30.8%	+19.0%	$14.82B	$814.57M	18.43	1,189
EXEL Exelixis	2.9598 of 5 stars	$57.22 -2.0%	$50.29 -12.1%	+44.6%	$14.18B	$2.44B	17.99	1,077
SMMT Summit Therapeutics	2.857 of 5 stars	$16.90 -5.3%	$25.91 +53.3%	-22.5%	$13.48B	N/A	N/A	265	Analyst Forecast Gap Up
BBIO BridgeBio Pharma	3.2885 of 5 stars	$66.58 0.0%	$102.61 +54.1%	+27.0%	$13.02B	$713.07M	N/A	839

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IOVA) was last updated on 9/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Iovance Biotherapeutics (IOVA) Competitors

IOVA vs. ASND, EXEL, SMMT, BBIO, and HALO

How does Iovance Biotherapeutics compare to Ascendis Pharma A/S?

Summary

How does Iovance Biotherapeutics compare to Exelixis?

Summary

How does Iovance Biotherapeutics compare to Summit Therapeutics?

Summary

How does Iovance Biotherapeutics compare to BridgeBio Pharma?

Summary

How does Iovance Biotherapeutics compare to Halozyme Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IOVA vs. The Competition

Iovance Biotherapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Iovance Biotherapeutics (IOVA) Competitors

IOVA vs. ASND, EXEL, SMMT, BBIO, and HALO

How does Iovance Biotherapeutics compare to Ascendis Pharma A/S?

Which has more risk and volatility, ASND or IOVA?

Is ASND or IOVA more profitable?

Do analysts prefer ASND or IOVA?

Does the media refer more to ASND or IOVA?

Which has stronger earnings and valuation, ASND or IOVA?

Do institutionals and insiders have more ownership in ASND or IOVA?

Summary

How does Iovance Biotherapeutics compare to Exelixis?

Which has better earnings & valuation, IOVA or EXEL?

Do analysts rate IOVA or EXEL?

Is IOVA or EXEL more profitable?

Does the media favor IOVA or EXEL?

Do institutionals and insiders have more ownership in IOVA or EXEL?

Which has more volatility & risk, IOVA or EXEL?

Summary

How does Iovance Biotherapeutics compare to Summit Therapeutics?

Which has higher valuation & earnings, IOVA or SMMT?

Is IOVA or SMMT more profitable?

Does the media favor IOVA or SMMT?

Do insiders and institutionals have more ownership in IOVA or SMMT?

Which has more risk and volatility, IOVA or SMMT?

Do analysts rate IOVA or SMMT?

Summary

How does Iovance Biotherapeutics compare to BridgeBio Pharma?

Which has more risk & volatility, IOVA or BBIO?

Is IOVA or BBIO more profitable?

Does the media favor IOVA or BBIO?

Which has preferable earnings and valuation, IOVA or BBIO?

Do insiders & institutionals have more ownership in IOVA or BBIO?

Do analysts rate IOVA or BBIO?

Summary

How does Iovance Biotherapeutics compare to Halozyme Therapeutics?

Which has better earnings and valuation, HALO or IOVA?

Is HALO or IOVA more profitable?

Does the media refer more to HALO or IOVA?

Do analysts rate HALO or IOVA?

Do insiders and institutionals hold more shares of HALO or IOVA?

Which has more risk and volatility, HALO or IOVA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IOVA vs. The Competition

Iovance Biotherapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools